Teva Pharmaceutical Revenue, Profits - TEVA Annual Income Statement

Add to My Stocks
$24.05 $0.17 (0.7%) TEVA stock closing price Jun 19, 2018 (Closing)

Fundamental analysis of TEVA stock involves analyzing its financial statements, apart from checking the Teva Pharmaceutical stock price. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has grown from 21.9B to 22.39B and how operating and non operating activities have impacted the TEVA stock. Along with Teva Pharmaceutical assets and Teva Pharmaceutical free cash flow, Teva Pharmaceutical profits as shown in profit and loss statement give key insights about the business. The net profit for 2017 is $-16.27B and the 2017 revenue is $22.39B.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Teva Pharmaceutical Revenues or Net Sales
22.39B21.9B19.65B20.27B20.31B20.32B18.31B16.12B13.9B11.09B
Cost Of Goods Sold (COGS)11.56B10.04B8.3B9.22B9.61B9.67B8.8B7.06B6.53B5.12B
Teva Pharmaceutical Gross Profit
10.83B11.86B11.36B11.06B10.71B10.65B9.52B9.07B7.37B5.97B
Research & Development Expense1.85B2.11B1.53B1.49B1.43B1.36B1.1B951M802M786M
Selling General & Admin Expense9.36B6B5.35B4.97B6.84B7.09B5.31B3.83B3.5B2.51B
Income Before Depreciation Depletion Amortization-384M3.75B4.48B4.6B2.44B2.21B3.11B4.28B3.07B2.67B
Depreciation Depletion Amortization17.1B900M--------
Non Operating Income-895M-2.03B-2.13B-963M-1.19B-386M-153M-635M-863M-1.84B
Interest Expense----------
Teva Pharmaceutical Pretax Income
-18.38B824M2.35B3.64B1.25B1.82B2.96B3.65B2.2B827M
Provision for Income Taxes-1.93B521M634M591M-43M-137M127M283M166M185M
MinorityInterest-184M-18M9M-13M-16M-53M9M--6M
Investment Gains Losses-3M8M-121M-5M-40M-46M-61M---
Other Income--------24M-33M-1M
Income Before Extraordinaries & Disc Operations-16.45B311M1.6B3.04B1.25B1.91B2.77B3.34B2B635M
Extraordinary Items & Discontinued Operations----------
Teva Pharmaceutical Profit/ Loss (Net Income)
-16.27B329M1.59B3.06B1.27B1.96B2.76B3.34B2B635M
Average Shares used to compute Diluted EPS1.02B961M864M858M850M873M893M921M896M820M
Average Shares used to compute Basic EPS1.02B955M855M853M849M872M890M896M872M780M
Income Before Nonrecurring Items4.25B5.17B4.7B4.35B4.26B4.67B4.44B4.13B3.03B2.37B
Income from Nonrecurring Items-20.52B-4.84B-3.11B-1.3B-2.99B-2.71B-1.68B-803M-1.03B-1.74B
Teva Pharmaceutical Earnings Per Share Basic Net
-16.260.071.843.581.492.253.103.722.290.81
Teva Pharmaceutical Earnings Per Share Diluted Net
-16.260.071.823.561.492.253.093.672.230.78
EPS Diluted Before Nonrecurring Items3.935.065.425.075.015.354.974.543.372.86
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.721.161.161.151.080.800.780.670.480.52
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

It is very helpful to read a report on Teva Pharmaceutical stock analysis. An investor must check the following items in an income statement:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $22.39B for this year of 2017. Our Teva Pharmaceutical revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: Most businesses like Teva Pharmaceutical try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The TEVA financials along with Teva Pharmaceutical historical stock prices provide a lot of details about the firm.

Teva Pharmaceutical Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
1.13
Operating Margin
30.1
Net Profit Margin
22.1
Dividend Yield
1.78%